Effectivity of Silymarin in improving hepatic fibrosis among patients with non alcoholic fatty liver disease – placebo controlled RCT

Anti-fibrotic effects of Silymarin among the patients of Nonalcoholic Fatty Liver Disease, a randomized control trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2024/011

Enrollment

Unknown

Registered

2024-03-18

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

Place of study: Medicine Out Patient Department, Chittagong Medical College Hospital, Chittagong, Bangladesh Patients who meet up inclusion and exclusions criteria will be informed in details about t

Eligibility

Inclusion criteria

Inclusion criteria: Fatty liver on ultrasonography of the hepatobilliary system - Hepatocellular steatosis is the hallmark of NAFLD, and steatosis in more than 5% of hepatocytes is required for the diagnosis of NAFLD. Fatty liver is diagnosed based on the following ultrasound parameters; parenchymal brightness, increased echogenicity of the liver parenchyma in comparison to the cortex of the right kidney, deep beam attenuation, bright vessel walls, and gallbladder wall definition.

Exclusion criteria

Exclusion criteria: 1. Alcoholic Fatty Liver Disease 2. Co-infection with HBV 3. Co-infection with HCV 4. Pregnancy

Design outcomes

Primary

Measure	Time frame
Decrease in Fibroscan score of Liver (Kpa) [After 1(one) year of treatment] Decrease in SGOT (IU/L) [ After 1(one) year of treatment]	—

Secondary

Measure	Time frame
SGOT/SGPT ratio [After 1(one) year of treatment]	—

Countries

Bangladesh

Contacts

Public ContactDr. Sonjoy Dey

Medical Officer

ayubmamunal@gmail.com+8801725876589

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026